EA033046B1 - Состав, содержащий пролекарство гемцитабина - Google Patents

Состав, содержащий пролекарство гемцитабина

Info

Publication number
EA033046B1
EA033046B1 EA201692422A EA201692422A EA033046B1 EA 033046 B1 EA033046 B1 EA 033046B1 EA 201692422 A EA201692422 A EA 201692422A EA 201692422 A EA201692422 A EA 201692422A EA 033046 B1 EA033046 B1 EA 033046B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formulations
gemcitabine
relates
alaninyl
benzoxy
Prior art date
Application number
EA201692422A
Other languages
English (en)
Other versions
EA201692422A1 (ru
Inventor
Хью Гриффит
Гордон Кенновин
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Priority claimed from GBGB1417646.5A external-priority patent/GB201417646D0/en
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA201692422A1 publication Critical patent/EA201692422A1/ru
Publication of EA033046B1 publication Critical patent/EA033046B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к фармацевтическим составам гемцитабин[фенил(бензокси-L-аланинил)]фосфата, монофосфатного производного хорошо известного противоопухолевого лекарственного средства гемцитабина. В частности, изобретение относится к составам, которые содержат полярный апротонный растворитель, предпочтительно диметилацетамид (ДМА). Составы, содержащие указанный растворитель, оказывают терапевтически эффективное лечение гемцитабин[фенил(бензокси-L-аланинил)]фосфатом. Изобретение также относится к способам применения указанных составов и наборов, содержащих указанные составы.
EA201692422A 2014-06-25 2015-06-25 Состав, содержащий пролекарство гемцитабина EA033046B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2050MU2014 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
GBGB1417646.5A GB201417646D0 (en) 2014-10-06 2014-10-06 Formulations of phosphate derivatives
PCT/GB2015/051858 WO2015198059A1 (en) 2014-06-25 2015-06-25 Formulation comprising a gemcitabine-prodrug

Publications (2)

Publication Number Publication Date
EA201692422A1 EA201692422A1 (ru) 2017-04-28
EA033046B1 true EA033046B1 (ru) 2019-08-30

Family

ID=53499028

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692422A EA033046B1 (ru) 2014-06-25 2015-06-25 Состав, содержащий пролекарство гемцитабина

Country Status (29)

Country Link
US (4) US10117888B2 (ru)
EP (2) EP3119794B1 (ru)
JP (3) JP6855248B2 (ru)
KR (2) KR20220104270A (ru)
CN (2) CN106470672B (ru)
AU (2) AU2015278900B2 (ru)
BR (1) BR112016025787B1 (ru)
CA (1) CA2944966C (ru)
CL (1) CL2016003261A1 (ru)
CY (1) CY1119772T1 (ru)
DK (1) DK3119794T3 (ru)
EA (1) EA033046B1 (ru)
ES (1) ES2655820T3 (ru)
HK (1) HK1244437A1 (ru)
HR (1) HRP20180007T1 (ru)
HU (1) HUE036011T2 (ru)
IL (2) IL248345B (ru)
LT (1) LT3119794T (ru)
MX (2) MX2020004054A (ru)
MY (1) MY186584A (ru)
NO (1) NO3119794T3 (ru)
PH (1) PH12016502552A1 (ru)
PL (1) PL3119794T3 (ru)
PT (1) PT3119794T (ru)
RS (1) RS56752B1 (ru)
SG (1) SG11201608809RA (ru)
SI (1) SI3119794T1 (ru)
TW (2) TWI674097B (ru)
WO (1) WO2015198059A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
PL3447061T3 (pl) 2011-03-01 2022-01-31 NuCana plc Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
RS58849B1 (sr) 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
WO2015198058A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
CN106470672B (zh) * 2014-06-25 2019-11-05 努卡那生物医药有限责任公司 包括吉西他滨前药的制剂
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
KR20230098915A (ko) 2014-11-28 2023-07-04 뉴카나 피엘씨 항암제로서 새로운 2' 및/또는 5' 아미노산 에스테르 포스포르아미데이트 3'-디옥시아데노신 유도체
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106539810B (zh) * 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
MX2018004137A (es) 2015-10-05 2018-06-13 NuCana plc Terapia de combinacion.
EP4011896A1 (en) 2015-12-11 2022-06-15 NuCana plc Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
CA3041121A1 (en) 2016-11-02 2018-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
MX2020000488A (es) 2017-07-20 2020-10-28 Centrexion Therapeutics Corp Metodos y composiciones para el tratamiento del dolor usando capsaicina.
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
WO2023076878A1 (en) * 2021-10-26 2023-05-04 Emphascience Inc. Ready-to-dilute formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087488A2 (en) * 2006-10-22 2008-07-24 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE60042073D1 (de) 1999-07-22 2009-06-04 Celmed Oncology Usa Inc Enzym katalisierte therapeutische aktivierung
CN1181829C (zh) * 2000-11-03 2004-12-29 中国人民解放军军事医学科学院附属医院 吉西他滨溶液制剂
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2006081364A2 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including ndga compounds, into animals
US8492400B2 (en) * 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
WO2011008985A2 (en) * 2009-07-15 2011-01-20 Georgia Tech Research Corporation Methods and compositions for improved delivery of therapeutic and diagnostic agents
MX2012005677A (es) * 2009-11-20 2012-08-23 Clavis Pharma Asa Formulaciones parentales de derivados de gemcitabina.
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
KR101231925B1 (ko) * 2010-10-27 2013-02-08 씨제이제일제당 (주) 젬시타빈의 전구약물 및 이의 제조방법
EP2804582B1 (en) * 2012-01-20 2016-03-30 Aratana Therapeutics NV Eye drop composition
CA2890359A1 (en) * 2012-11-07 2014-05-15 Zucai SUO Substituted gemcitabine aryl amide analogs and treatment methods using same
RS58849B1 (sr) 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
WO2015198058A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
CN106470672B (zh) 2014-06-25 2019-11-05 努卡那生物医药有限责任公司 包括吉西他滨前药的制剂
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3197456B2 (en) 2015-05-14 2023-10-11 NuCana plc Cancer treatments
MX2018004137A (es) 2015-10-05 2018-06-13 NuCana plc Terapia de combinacion.
EP4011896A1 (en) 2015-12-11 2022-06-15 NuCana plc Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
WO2017109486A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087488A2 (en) * 2006-10-22 2008-07-24 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bilir A., Guneri A.D., Altinoz M.A.: "Acetaminophen and DMSO modulate growth and gemcitabine cytotoxicity in FM3A breast cancer cells in vitro", NEOPLASMA, vol. 51, no. 6, 1 January 2004 (2004-01-01), 2004, pages 460-464, XP055205686, Retrieved from the Internet: URL:http://www.elis.sk/download_file.php?product_id=704&session_idd4h527oor14r6t55q2codkfqq1 [retrieved on 2015-07-31], abstract, page 463, right-hand column, lines 24-26 *
MAGDALENA SLUSARCZYK, MONICA HUERTA LOPEZ, JAN BALZARINI, MALCOLM MASON, WEN G. JIANG, SARAH BLAGDEN, EMELY THOMPSON, ESSAM GHAZAL: "Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 57, no. 4, 27 February 2014 (2014-02-27), pages 1531 - 1542, XP055205033, ISSN: 00222623, DOI: 10.1021/jm401853a *

Also Published As

Publication number Publication date
TW201613611A (en) 2016-04-16
US11707477B2 (en) 2023-07-25
TW201945007A (zh) 2019-12-01
MX2016015629A (es) 2017-08-02
NO3119794T3 (ru) 2018-03-10
IL248345B (en) 2020-10-29
PL3119794T3 (pl) 2018-04-30
MY186584A (en) 2021-07-28
US20170095498A1 (en) 2017-04-06
SI3119794T1 (en) 2018-02-28
US20190022118A1 (en) 2019-01-24
CY1119772T1 (el) 2018-06-27
KR102421929B1 (ko) 2022-07-15
LT3119794T (lt) 2018-02-12
CA2944966C (en) 2022-10-25
DK3119794T3 (en) 2018-01-22
US10786523B2 (en) 2020-09-29
NZ725009A (en) 2021-02-26
TWI765176B (zh) 2022-05-21
BR112016025787A2 (pt) 2017-08-15
AU2015278900B2 (en) 2019-04-04
KR20220104270A (ko) 2022-07-26
EP3119794A1 (en) 2017-01-25
PH12016502552A1 (en) 2017-04-10
JP6855248B2 (ja) 2021-04-07
IL248345A0 (en) 2016-11-30
SG11201608809RA (en) 2016-11-29
CA2944966A1 (en) 2015-12-30
US20220031727A1 (en) 2022-02-03
EP3269391A1 (en) 2018-01-17
IL276199B (en) 2022-04-01
ES2655820T3 (es) 2018-02-21
JP7329025B2 (ja) 2023-08-17
CN106470672B (zh) 2019-11-05
HUE036011T2 (hu) 2018-06-28
AU2019204557B2 (en) 2020-08-27
US20200397810A1 (en) 2020-12-24
JP6970221B2 (ja) 2021-11-24
IL276199A (en) 2020-09-30
AU2015278900A1 (en) 2016-10-27
AU2019204557A1 (en) 2019-07-18
HRP20180007T1 (hr) 2018-02-23
CN110882268A (zh) 2020-03-17
CL2016003261A1 (es) 2017-10-06
JP2020079255A (ja) 2020-05-28
WO2015198059A1 (en) 2015-12-30
HK1244437A1 (zh) 2018-08-10
PT3119794T (pt) 2018-01-15
BR112016025787B1 (pt) 2022-12-13
JP2017519022A (ja) 2017-07-13
US11040051B2 (en) 2021-06-22
MX2020004054A (es) 2021-11-30
CN106470672A (zh) 2017-03-01
KR20170042501A (ko) 2017-04-19
EP3119794B1 (en) 2017-10-11
EA201692422A1 (ru) 2017-04-28
US10117888B2 (en) 2018-11-06
TWI674097B (zh) 2019-10-11
RS56752B1 (sr) 2018-04-30
JP2022031659A (ja) 2022-02-22

Similar Documents

Publication Publication Date Title
EA033046B1 (ru) Состав, содержащий пролекарство гемцитабина
MX2023010042A (es) Polinucleotidos moduladores.
MX2023008693A (es) Polinucleotidos moduladores.
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
EP3313404A4 (en) THERAPEUTIC COMPOSITIONS, ASSOCIATIONS AND METHODS OF USE
EP3389725A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
EP3349762A4 (en) CO-CRYSTALS OF SGLT2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
MX2021006734A (es) Metodo para tratar el cancer.
EP3307754A4 (en) NICOTINAMIDRIBOSIDE AND PTEROSTODY COMPOSITIONS AND METHOD FOR TREATING SKIN DISEASES
MX2020004454A (es) Manufactura de productos de interpolimero de etileno a una mayor tasa de produccion.
EP3487537A4 (en) ZWITTERONIC MICROGELS, THEIR ASSEMBLIES AND ASSOCIATED FORMULATIONS, AND METHODS OF USE
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
EP3349599A4 (en) INHIBITABLE NICOTINE FORMULATIONS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP3380525A4 (en) PHARMACEUTICAL FORMULATIONS AND METHODS OF USE
GB201522764D0 (en) Formulations of phosphate derivatives
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3471738A4 (en) PHOSPHATE-SUBSTITUTED CYCLIC NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
EP3244900A4 (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
EP3313520A4 (en) Therapeutic uses of berberine formulations
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
EP3325019A4 (en) COMPOSITES AND COMPOSITIONS FOR USE IN THERAPEUTIC PURPOSE AND METHODS OF MAKING AND USING SAME
EP3506947A4 (en) PHARMACEUTICAL FORMULATIONS OF REGADENOSONE
EP3471739A4 (en) USE OF PHOSPHATE-SUBSTITUTED CYCLIC NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES
EP3471737A4 (en) CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE COMPOUND AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES